Meeting
2015 ASCO Annual Meeting
Use of a novel radio-sensitizer for treatment of GBM.
Authors
John Lloyd Gainer
Diffusion Pharmaceuticals LLC, Charlottesville, VA
John Lloyd Gainer , Jason Sheehan , James Mitchell Larner , David Randolph Jones
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01465347
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2031)
DOI
10.1200/jco.2015.33.15_suppl.2031
Abstract #
2031
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.
First Author: Frank Anton Giordano
Poster
2022 ASCO Annual Meeting
Population-based retrospective analysis of response assessment criteria in patients with glioblastoma.
First Author: Parandoush Abbasian
Poster
2018 ASCO Annual Meeting
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
First Author: Damien Pouessel
Poster
2017 ASCO Annual Meeting
Phase I/II trial of cetuximab with 5-fluorouracil and mitomycin C concurrent with radiotherapy in patients with muscle invasive bladder cancer.
First Author: Syed A. Hussain